ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the usage of its “at the market” equity providing program.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out a “at the market” equity offering system under which Acasti may well issue and promote from time to time its common shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been marketed at prevailing market costs averaging US$1.0747 per share. No securities had been offered through the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with extra flexibility in its continuous review process to enjoy as well as evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy and safety for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements of this press release which are not statements of historical or current truth constitute “forward looking information” to the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking claims involve known and unknown risks, uncertainties, along with other unknown factors that can cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the particular date of this press release. Forward-looking statements in this press release include, but are not restricted to, statements or info concerning Acasti’s strategy, succeeding operations and the review of its of strategic options.
The forward looking assertions contained in this specific press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and on the investor area of Acasti’s site at www.acastipharma.com. Many forward-looking statements in this press release are available as of the date of this press release.
ACST Stock – Acasti does not undertake to upgrade some such forward-looking statements whether as a consequence of brand new info, future events or even otherwise, except as required by law. The forward-looking claims contained herein are also subject generally to risks and assumptions and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the use